Joseph F Grosso
Overview
Explore the profile of Joseph F Grosso including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
9268
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D, et al.
JAMA Oncol
. 2019 Jul;
5(10):1411-1420.
PMID: 31343665
Importance: Nivolumab, a monoclonal antibody that inhibits programmed cell death 1, is approved by the US Food and Drug Administration for treating advanced melanoma, renal cell carcinoma (RCC), non-small cell...
2.
Lewis K, Selby M, Masters G, Valle J, Dito G, Curtis W, et al.
Oncoimmunology
. 2018 Jan;
7(1):e1377873.
PMID: 29296539
Recent advances in cancer treatment with checkpoint blockade of receptors such as CTLA-4 and PD-1 have demonstrated that combinations of agents with complementary immunomodulatory effects have the potential to enhance...
3.
Majzner R, Simon J, Grosso J, Martinez D, Pawel B, Santi M, et al.
Cancer
. 2017 Jun;
123(19):3807-3815.
PMID: 28608950
Background: Programmed death 1 (PD-1) signaling in the tumor microenvironment dampens immune responses to cancer, and blocking this axis induces antitumor effects in several malignancies. Clinical studies of PD-1 blockade...
4.
Lesokhin A, Ansell S, Armand P, Scott E, Halwani A, Gutierrez M, et al.
J Clin Oncol
. 2016 Jun;
34(23):2698-704.
PMID: 27269947
Purpose: Cancer cells can exploit the programmed death-1 (PD-1) immune checkpoint pathway to avoid immune surveillance by modulating T-lymphocyte activity. In part, this may occur through overexpression of PD-1 and...
5.
Ansell S, Lesokhin A, Borrello I, Halwani A, Scott E, Gutierrez M, et al.
N Engl J Med
. 2014 Dec;
372(4):311-9.
PMID: 25482239
Background: Preclinical studies suggest that Reed-Sternberg cells exploit the programmed death 1 (PD-1) pathway to evade immune detection. In classic Hodgkin's lymphoma, alterations in chromosome 9p24.1 increase the abundance of...
6.
Simons B, Durham N, Bruno T, Grosso J, Schaeffer A, Ross A, et al.
J Pathol
. 2014 Oct;
235(3):478-89.
PMID: 25348195
Inflammation is associated with several diseases of the prostate including benign enlargement and cancer, but a causal relationship has not been established. Our objective was to characterize the prostate inflammatory...
7.
Wada S, Harris T, Tryggestad E, Yoshimura K, Zeng J, Yen H, et al.
Int J Radiat Oncol Biol Phys
. 2013 Sep;
87(4):769-76.
PMID: 24064321
Purpose: To optimize the combination of ionizing radiation and cellular immunotherapy using a preclinical autochthonous model of prostate cancer. Methods And Materials: Transgenic mice expressing a model antigen under a...
8.
Wada S, Jackson C, Yoshimura K, Yen H, Getnet D, Harris T, et al.
J Transl Med
. 2013 Apr;
11:89.
PMID: 23557194
Background: The FDA recently approved an anti-CTLA-4 antibody (Iplimumab) for the treatment of metastatic melanoma. This decision was based on Phase III results, which demonstrate that blocking this immune checkpoint...
9.
Grosso J, Jure-Kunkel M
Cancer Immun
. 2013 Feb;
13:5.
PMID: 23390376
Cytotoxic T lymphocyte antigen-4 (CTLA-4) is a key negative regulator of T cell activation. A complex integration of positive and negative co-stimulatory signals in the well-defined B7:CD28/CTLA-4 pathway modulates the...
10.
Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P, et al.
N Engl J Med
. 2012 Jun;
366(26):2455-65.
PMID: 22658128
Background: Programmed death 1 (PD-1) protein, a T-cell coinhibitory receptor, and one of its ligands, PD-L1, play a pivotal role in the ability of tumor cells to evade the host's...